Acyclovir (Aciclovir) sodium 是一种有效的口服抗病毒药物。Acyclovir sodium 具有抗疱疹活性，对HSV-1和HSV-2的IC50值分别为 0.85 μM 和 0.86 μM。Acyclovir sodium 诱导细胞周期扰动和凋亡 (apoptosis)。Acyclovir sodium 可预防急性白血病的诱导疗法中的细菌感染。
| 生物活性 | Acyclovir (Aciclovir) sodium is a potent, orally active antiviral agent. Acyclovir sodium has antiherpetic activity withIC50values of 0.85 μM and 0.86 μM forHSV-1andHSV-2, respectively. Acyclovir sodium induces cell cycle perturbation andapoptosis. Acyclovir sodium preventsbacterialinfections during induction therapy for acute leukaemia[1][2][3][4]. |
| IC50& Target[2] | HSV-1 | HSV-2 | HSV-1 0.85 μM (IC50) | HSV-2 0.86 μM (IC50) |
|
体外研究
(In Vitro) | Acyclovir (Aciclovir) sodium (3-100 μM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) reduces cell viability in a dose- and time-dependent[1].
Acyclovir (Aciclovir) sodium (10-100 μM; 24-72 hours; Jurkat cells) blocks DNA synthesis, thereby arresting the cell cycle in G2/M and S phases and increasing the sub-G1 hypodiploid peak in a dose-dependent manner[1].
Acyclovir (Aciclovir) sodium (10-100 μM; 24-72 hours; Jurkat cells) induces apoptosis through activates caspase-3 and presences nuclear DNA fragmentation[1].
Cell Viability Assay[1] | Cell Line: | Jurkat, U937 and K562 leukemia cells | | Concentration: | 3, 10, 30 and 100 μM | | Incubation Time: | 24, 48 and 72 hours | | Result: | Showed a dose- and time-dependent reduction of cell viability. |
Apoptosis Analysis[1] | Cell Line: | Jurkat cells | | Concentration: | 10 and 100 μM | | Incubation Time: | 24, 48 and 72 hours | | Result: | Increased of caspase-3 activity and cleavaged the internucleosomal DNA. |
Cell Cycle Analysis[1] | Cell Line: | Jurkat cells | | Concentration: | 10 and 100 μM | | Incubation Time: | 24, 48 and 72 hours | | Result: | Revealed a dose-dependent accumulation of cells in S phase after 24 and 48 h. Showed a dose-dependent increase of the sub-G1 hypodiploid peak after 72 h. |
|
体内研究
(In Vivo) | Acyclovir (Aciclovir) sodium (20 mg/kg; p.o.; three times daily; for 10 d; BALB/c mice) suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production[3]
| Animal Model: | Specific-pathogen-free BALB/c mice (7-week-old) infected with HSV-1[3] | | Dosage: | 20 mg/kg | | Administration: | Oral administration; three times daily; for 10 days | | Result: | Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com